Innate Pharma Net Tangible Assets

Innate Pharma's net tangible assets stands at $-40M as of June 2026. That compares with $5.1M in the prior-year period — down 887.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Innate Pharma reported $-40M in net tangible assets versus $5.1M a year earlier — a 887.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $5.1M in the prior-year period — down 887.2% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Innate Pharma's net tangible assets evolved across reporting periods, while the comparison chart places IPHA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Innate Pharma's reading of $-40M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.